Intelligence Report · ~12 min read
Travere Therapeutics Intelligence Report
Generated from 1 signals · 2 evidence sources
Type
Company Intelligence ReportGenerated
Jun 10, 2026
Confidence
Moderate Confidence · 70%
Evidence
6 items
Sources
7
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Travere Therapeutics maintains an active intelligence profile across Nephrology, SGLT2 Inhibitor. 1 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with moderate portfolio impact. Evidence coverage stands at 70% across 2 tracked sources. Highest-priority development: Over-The-Counter Monograph Drug User Fee Program (OMUFA). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for TRAVERE; the same agency is already in play for this signal, so precedent weight is higher.
Key Developments
Material intelligence events ranked by strategic relevance.
- regulatory
Over-The-Counter Monograph Drug User Fee Program (OMUFA)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Generic Drugs: Questions & Answers
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — FILSPARI (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — FILSPARI (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA Drug Competition Action Plan | Improving the efficiency of the generic drug development, review, and approval process
Regulatory precedent may inform portfolio positioning
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Opportunity score 24 with buyer quality 8 (Mid-Market). Competitive pressure: Low. Portfolio impact: Moderate.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
Over-The-Counter Monograph Drug User Fee Program (OMUFA)
Moderate Confidence · 66%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceGeneric Drugs: Questions & Answers
Moderate Confidence · 66%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — FILSPARI (SUPPL)
Moderate Confidence · 66%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — FILSPARI (SUPPL)
Moderate Confidence · 66%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA Drug Competition Action Plan | Improving the efficiency of the generic drug development, review, and approval process
Moderate Confidence · 84%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- FDA Accepts Supplement for FILSPARI (SPARSENTAN) by TRAVERE
Nephrology · SGLT2 Inhibitor